Trade Subcommittee Hearing on U.S.-India Trade Relations: Opportunities and Challenges

Wednesday, March 13, 2013 - 10:00am
1100 Longworth House Office Building

Focus Of The Hearing
The hearing will provide an opportunity to explore current U.S.-India trade issues such as:  (1) deepening and expanding the long-term trade and investment relationship with India; (2) completing a Bilateral Investment Treaty, addressing investment caps, and exploring new investment opportunities; (3) addressing agricultural market access barriers; (4) evaluating India’s National Manufacturing Policy and other forced localization policies including the Preferential Market Access (PMA) on information technology products; (5) ensuring the protection of intellectual property rights; (6) addressing the issuance of compulsory licenses, patent revocations, and other policies on pharmaceuticals; (7) examining India’s system of cascading tariffs, taxes, and other import charges; and (8) advancing WTO negotiations, including “post-Doha” issues such as an international services agreement, Information Technology Agreement expansion, and a trade facilitation agreement in partnership with India. 

Hearing Advisory
Chairman Nunes Announces Hearing on U.S.-India Trade Relations: Opportunities and Challenges

Public Submissions For Record
Please click here to submit a statement or letter for the record.

Opening Statements

Rangel Opening Statement at Trade Subcommittee Hearing on U.S.-India Trade Relations

Dan Twining
Senior Fellow for Asia, German Marshall Fund of the United States
(Truth in Testimony)

Arvind Subramanian
Senior Fellow, Peterson Institute for International Economics, and the Center for Global Development
(Truth in Testimony)

Ambassador Allen F. Johnson
Founder, Allen F. Johnson & Associates, and Former Chief Agricultural Negotiator, Office of the United States Trade Representative
(Truth in Testimony)

Dean Garfield
President & CEO, Information Technology Industry Council
(Truth in Testimony)

Roy Waldron
Senior Vice President and Chief Intellectual Property Counsel, Pfizer
(Truth in Testimony)

113th Congress